Royalty Pharma plc (NASDAQ: RPRX), a leading acquirer of biopharmaceutical royalties, witnessed a remarkable 5.11% surge in its stock price on November 7, 2024. This surge came on the heels of the company's impressive third-quarter earnings report, released on November 6, 2024.

In the third quarter, Royalty Pharma reported a 15% growth in both portfolio receipts and royalty receipts, showcasing its robust financial performance. Furthermore, the company raised its full-year 2024 guidance, expecting portfolio receipts to range between $2.75 billion and $2.8 billion, underscoring its confidence in continued growth.

Beyond its strong financial results, Royalty Pharma has been actively deploying capital to acquire new royalties. Year-to-date, the company has invested approximately $2.6 billion in strategic acquisitions, including royalties on three novel therapies for schizophrenia, glioma, and ulcerative colitis. These acquisitions are expected to further diversify Royalty Pharma's portfolio and drive future growth.